| Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial AT Taher, MD Cappellini, A Kattamis, E Voskaridou, S Perrotta, AG Piga, ... The Lancet Haematology 9 (10), e733-e744, 2022 | 41 | 2022 |
| Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine … TP Vassilakopoulos, MN Dimopoulou, MK Angelopoulou, K Petevi, ... The Oncologist 21 (3), 343-353, 2016 | 32 | 2016 |
| The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/βthal), correlate with markers … K Larissi, M Politou, A Margeli, C Poziopoulos, P Flevari, E Terpos, ... Blood Cells, Molecules, and Diseases 77, 137-141, 2019 | 23 | 2019 |
| A hepcidin mimetic, PTG-300, demonstrates pharmacodynamic effects indicating reduced iron availability in transfusion-dependent beta-thalassemia subjects A Lal, E Voskaridou, P Flevari, A Taher, LP Chew, F Valone, S Gupta, ... Hemasphere 4 (S1), 110, 2020 | 10 | 2020 |
| The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review M Zachou, P Flevari, N Nasiri-Ansari, C Varytimiadis, E Kalaitzakis, ... European Journal of Clinical Pharmacology 80 (1), 127-150, 2024 | 7 | 2024 |
| Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome E Lakiotaki, G Levidou, MK Angelopoulou, C Adamopoulos, G Pangalis, ... Scientific reports 6 (1), 21252, 2016 | 6 | 2016 |
| Prognostic factors in patients with Hodgkin lymphoma (HL) and a negative PET/CT after ABVD chemotherapy: potential applications for the design of follow-up strategies T Vassilakopoulos, G Pangalis, G Boutsikas, P Rontogianni, S Masouridis, ... Haematologica 97, 87-88, 2012 | 5 | 2012 |
| Outcomes of pregnancies in patients with Gaucher Disease: The experience of a center of excellence on rare metabolic Disease-Gaucher Disease, in Greece V Komninaka, P Flevari, T Marinakis, G Karkaletsis, L Malakou, K Repa European Journal of Obstetrics & Gynecology and Reproductive Biology 254 …, 2020 | 4 | 2020 |
| Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction E Voskaridou, M Aimilia, P Flevari, M Dimopoulou, V Komninaka, K Repa, ... Blood 134, 4829, 2019 | 3 | 2019 |
| Pure red cell aplasia complicating the course of long-standing mantle cell lymphoma A Kanellopoulos, K Koutsi, G Georgiou, T Ntalagiorgos, K Petevi, ... International journal of hematology 99, 777-781, 2014 | 3 | 2014 |
| Three-year antibiotic stewardship in a Greek maternity hospital P Flevari, V Bentouli, E Kada, I Zorou, MA Stamouli, I Elefsiniotis, ... Archives of Hellenic Medicine 27 (2), 208-214, 2010 | 3 | 2010 |
| Case report of myelodysplastic syndrome in a sickle-cell disease patient treated with hydroxyurea and literature review P Flevari, E Voskaridou, F Galactéros, G Cannas, G Loko, L Joseph, ... Biomedicines 10 (12), 3201, 2022 | 2 | 2022 |
| Difficulties in diagnosing and treating disseminated Bacillus Calmette-Guerin (BCG) infection after intravesical BCG therapy in a patient with liver cirrhosis: a case report C Vallilas, M Zachou, P Dolkiras, S Sakellariou, CA Constantinou, ... The American Journal of Case Reports 22, e933006-1, 2021 | 2 | 2021 |
| Surveillance System and Prevalence of Healthcare‐Associated Infections in a Maternity Hospital P Flevari, I Zorou, A Tsakris, G Saroglou International Scholarly Research Notices 2013 (1), 849493, 2013 | 2 | 2013 |
| THE PROGNOSTIC SIGNIFICANCE OF PET SCAN BEFORE AND AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS M Angelopoulou, M Moschogiannis, P Rondogianni, V Pappis, ... Haematologica 97, 178-179, 2012 | 2 | 2012 |
| ERN-EuroBloodNet European registry of patients affected by red blood cell disorders and COVID-19 P Velasco, F Longo, A Piolatto, EJ Bardón-Cancho, B Ponce-Salas, ... Blood 138 (Supplement 1), 4058-4058, 2021 | 1 | 2021 |
| Non Invasive Evaluation of Bone Marrow Activity in Patients with Sickle Cell Disease: Correlation with Disease Features, Genotype, Markers of Erythropoiesis, Iron Metabolism … I Papassotiriou, P Flevari, C Poziopoulos, S Zaliou, V Tsaousis, K Larissi, ... Blood 134, 4821, 2019 | 1 | 2019 |
| Silent Cerebral Ischemia and Thromboembolic Events in Sickle Cell Disease: Analysis of Coagulation Parameters and Thromboelastography M Dimopoulou, M Politou, K Stavroula, D Koutsouri, P Tsioutsias, ... Haematologica 102, 605-606, 2017 | 1 | 2017 |
| Preemptive use of plerixafor in patients with lymphoproliferative diseases undergoing haematopoietic stem cell mobilization V Telonis, T Vassilakopoulos, E Lalou, G Boutsikas, Z Galani, ... BONE MARROW TRANSPLANTATION 48, S119-S120, 2013 | 1 | 2013 |
| Pulmonary Hypertension in Sickle Cell Disease: Novel Findings of Gene Polymorphisms Related to Pathophysiology S Chatzidavid, P Flevari, I Tombrou, G Anastasiadis, M Dimopoulou International Journal of Molecular Sciences 25 (9), 4792, 2024 | | 2024 |
